Within 2 weeks after symptom onset |
Molecular test (ideally nasopharyngeal or nasal swabs) |
To detect viral RNA (preferred test) |
Provides the most sensitive and specific means of confirming a clinical diagnosis |
Expensive; requires specialised skills and instruments; testing is not at point of need; results can take longer than 24–48 h |
Antigen rapid detection test (ideally nasopharyngeal or nasal swabs) |
To detect viral protein if molecular testing is not available or the results are delayed |
Can provide results within 15–20 min; can be done outside of a laboratory setting with minimal training; cheaper and faster to manufacture than molecular tests |
Not as sensitive as molecular tests; more difficult to assure quality, especially with self-tests, compared with laboratory-based tests; if a patient tests negative, it is necessary to collect another sample for molecular testing |
More than 2 weeks after symptom onset |
Molecular test, antigen rapid detection test, and antibody test |
To establish a late or retrospective diagnosis by using antibody tests if molecular and antigen rapid tests are both negative |
Can provide results in 15–20 min if a rapid antibody test or within 24 h if a laboratory-based assay |
Antibody tests can be non-specific and cause false-positive results; can be difficult to determine if seropositivity is vaccine-induced or natural |
Patient has persistently negative test results but there is a high index of suspicion based on clinical presentation or other criteria (eg, chest CT scan findings) |
Repeat molecular or antigen rapid detection test using a lower respiratory tract specimen (eg, sputum or bronchioalveolar lavage sample, or tracheal aspirate and blood for an antibody test) and antibody test |
To confirm a clinical diagnosis |
Confirms clinical diagnosis if the lower respiratory tract specimen is positive; enables retrospective diagnosis of past or recent infection if the antibody test is positive |
Antibody tests can be non-specific and cause false-positive results |